Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
296.61
-0.89 (-0.30%)
Jul 28, 2026, 1:32 PM EDT - Market open
Ligand Pharmaceuticals Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 274.48 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 |
Revenue Growth | 51.24% | 60.40% | 27.28% | -33.09% | -18.75% | 47.68% |
Gross Profit Gross Profit Growth | 261.5 | 253.54 | 156.06 | 120.8 | 143.42 | 179.37 |
Operating Income Operating Income Growth | 100.78 | 41 | -22.61 | 9.82 | 3.04 | 103.85 |
Net Income Net Income Growth | 153.56 | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 |
Earnings Per Share EPS Growth | 7.37 | 6.13 | -0.22 | 2.94 | -0.31 | 3.31 |
EPS Growth | - | - | - | - | - | 748.72% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue from Intangible Royalty Assets Revenue from Intangible Royalty Assets Growth | 143.88 | 132.53 | 95.33 | 83.91 | 72.53 | 48.93 |
Income from Financial Royalty Assets Income from Financial Royalty Assets Growth | 32.59 | 28.47 | 13.44 | 1.05 | 0.39 | - |
Captisol Captisol Growth | 35.41 | 40.21 | 30.88 | 28.37 | 104.5 | 164.25 |
Contract Revenue and Income Contract Revenue and Income Growth | 62.6 | 66.87 | 27.48 | 17.98 | 18.84 | - |
Revenue (Total) Revenue (Total) Growth | 274.48 | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 779.41 | 733.52 | 256.17 | 170.31 | 211.87 | 341.11 |
Total Debt Total Debt Growth | 451.98 | 451.49 | 7.08 | 6.17 | 87.75 | 324.39 |
Net Cash (Debt) Net Cash Growth | 327.43 | 282.03 | 249.08 | 164.14 | 124.12 | 16.72 |
Net Cash Growth | 60.15% | 13.23% | 51.75% | 32.24% | 642.28% | - |
Net Cash Per Share Net Cash Per Share Growth | 16.06 | 13.90 | 13.62 | 9.24 | 7.36 | 0.97 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 123.5 | 49.36 | 97.05 | 49.58 | 137.85 | 78.8 |
Capital Expenditures CapEx Growth | -0.47 | -0.45 | -1.82 | -3.52 | -17.92 | -8.76 |
Free Cash Flow Free Cash Flow Growth | 123.03 | 48.91 | 95.23 | 46.06 | 119.93 | 70.04 |
Free Cash Flow Growth | 141.52% | -48.64% | 106.76% | -61.60% | 71.23% | 39.72% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 95.27% | 94.57% | 93.37% | 91.99% | 73.08% | 74.26% |
Operating Margin | 36.72% | 15.29% | -13.53% | 7.48% | 1.55% | 42.99% |
Pretax Margin | 74.33% | 62.63% | 4.51% | 52.24% | 18.48% | 22.14% |
Profit Margin | 85.74% | 46.42% | -2.41% | 40.98% | -2.66% | 31.61% |
FCF Margin | 44.82% | 18.24% | 56.98% | 35.07% | 61.11% | 29.00% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 39.67 | 30.84 | - | 24.29 | - | 46.66 |
Forward PE | 54.47 | 35.20 | 53.58 | 35.07 | 298.37 | 298.37 |
P/FCF Ratio | 48.01 | 76.44 | 21.50 | 27.22 | 9.44 | 36.98 |
PS Ratio | 21.52 | 13.95 | 12.25 | 9.55 | 5.77 | 10.72 |